MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-PB-20-0005338
Unimarck Pharma (India) Limited - pharma in Chandigarh, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹58.24 Cr
▲ 7% YoY
Net loss · FY 2025
₹58.41 Lakh
Net margin -1%
EBITDA · FY 2025
₹2 Cr
EBITDA margin 3.4%
Authorised capital
₹2 Cr
Registered with MCA
Paid-up capital
₹1.79 Cr
Issued & subscribed
Open charges
₹21.65 Cr
Satisfied ₹37 Cr
Company age
42 yrs
Est. 1984
Employees · EPFO
409
Provident fund records
About Unimarck Pharma (India) Limited
Data last updated:
Unimarck Pharma (India) Limited is a public limited company based in Chandigarh, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 12 March 1984 and has been in existence for over 42 years.
The company is registered with the Registrar of Companies (ROC), Chandigarh, under CIN U24232CH1984PLC005768. Its GSTIN is 04AAACU2585M1Z3 (Chandigarh). The company holds 10 GST registrations, of which 9 are active.
The company has an authorised share capital of ₹2 Cr and a paid-up capital of ₹1.79 Cr. It was formerly known as Unimarck Pharma Private Limited. It is led by directors including Mandeep Singh (Managing Director) and Gagandeep Bhatia (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at SCO 56 & 57 Next To Gpo, Shopping Plaza 17D Sector 17, Chandigarh, India – 160017.
As per the financials filed for FY 2025, the company reported a revenue of ₹58.24 Cr, a growth of 7% compared to the previous year. For the same year it recorded a net loss of ₹58.41 Lakh (net margin -1%) and EBITDA of ₹2 Cr (EBITDA margin 3.4%). Revenue has declined at a compounded annual rate (CAGR) of 5% over three years and 1% over five years.
The company has about 409 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Uniqaya and Unimarck Pharma. As per MCA filings, the company has open charges of ₹21.65 Cr and satisfied charges of ₹37 Cr on record. Court records list 17 cases involving the company, including 13 filed by the company and 4 filed against it; 7 cases are pending. The company has 5 deals on record (3 secondary share transfers, 2 funding rounds), with disclosed funding of ₹99.4 Lakh; the latest was in March 2022. Its 5 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 1 larger and 4 smaller; the largest is Ocean Healthcare Private Limited with revenue of ₹58.49 Cr.
Unimarck Pharma (India) Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-PB-20-0005338). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website unimarckpharma.com.
Company details
CIN U24232CH1984PLC005768
Registration Number 005768
Incorporation Date 12 March 1984
ROC Chandigarh
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-PB-20-0005338
Key People
Mandeep Singh Managing Director Gagandeep Bhatia Whole-Time Director Harsh Bhatia Whole-Time Director Recognitions & Rankings of Unimarck Pharma (India)
Contact details
Unimarck Pharma (India) Limited's registered office is in Chandigarh, Chandigarh. Its website is unimarckpharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressSCO 56 & 57 Next To Gpo, Shopping Plaza 17D Sector 17, Chandigarh, India – 160017
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Unimarck Pharma (India) Limited, buy the company report.
Comprehensive company report
Unimarck Pharma (India) Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Unimarck Pharma (India) operates two associated brands: Uniqaya and Unimarck Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Sells skincare items including sunscreens and moisturizers through e-commerce. | uniqaya.com | |
| Pharmaceutical manufacturing and services in India focusing on ethical, generic, and cosmoceutical divisions. | unimarckpharma.com |
Business activity
The main business activity of Unimarck Pharma (India) is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Unimarck Pharma (India) Limited, buy the company report.
Financials of Unimarck Pharma (India) Limited
FY 2025 filings availableUnimarck Pharma (India) Limited reported revenue of ₹58.24 Cr (up 7% YoY) for FY 2025.
Revenue · FY 2025
₹58.24 Cr ▲ 7%
Net loss · FY 2025
₹58.41 Lakh margin -1%
EBITDA · FY 2025
₹2 Cr margin 3.4%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 7%
3 years · compounded
▼ 5%
5 years · compounded
▼ 1%
EBITDA CAGR growth
1 year
▼ 4%
3 years · compounded
▼ 23%
5 years · compounded
▼ 13%
Revenue rose 7% in the latest year, though over five years it has declined at a compounded annual rate (CAGR) of 1%. EBITDA fell 4% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹2 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹58.41 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 3.4% | ||||
| Net Profit Margin | -1% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Unimarck Pharma (India) Limited, buy the company report.
Board of directors of Unimarck Pharma (India) Limited
Unimarck Pharma (India) has 4 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Gagandeep Bhatia | Whole-Time Director | 10 Aug 2000 | 26 Years 2 Months | Current |
| Harleen Kaur Bhatia Also directs: Teriot Pharmaceuticals Private Limited | Director | 01 Apr 2023 | 3 Years 6 Months | Current |
| Harsh Bhatia | Whole-Time Director | 12 Mar 1984 | 42 Years 7 Months | Current |
| Mandeep Singh Also directs: Teriot Pharmaceuticals Private Limited | Managing Director | 03 Dec 2015 | 10 Years 10 Months | Current |
Peer comparison
Unimarck Pharma (India) Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Ocean Healthcare Private Limited | ₹58.49 Cr (FY 2025) | -8.0% | Egmore Nungambakkm, Tamil Nadu, India | |||
| Unimarck Pharma (India) Limitedthis company | ₹58.24 Cr (FY 2025) | -₹58.41 Lakh | -1% | 7.0% | 409 | Chandigarh, India |
| Livealth Biopharma Private Limited | ₹58.19 Cr (FY 2025) | -9.0% | Mumbai, Maharashtra, India | |||
| Uma Ayurvedics Private Limited | ₹58.01 Cr (FY 2024) | 61.0% | Uttar Pradesh, India | |||
| Stedman Pharmaceuticals Private Limited | ₹57.77 Cr (FY 2024) | 9.0% | Chennai, Tamil Nadu, India | |||
| And Healthcare Limited | ₹57.48 Cr (FY 2024) | 24.0% | Mohali, Punjab, India |
To see the full peer comparison of Unimarck Pharma (India) Limited, buy the company report.
Auditor
Unimarck Pharma (India) Limited is audited by RAVI SUD AND ASSOCIATES for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| RAVI SUD AND ASSOCIATES | FY 2024 | 023111N |
Shareholding
The shareholding of Unimarck Pharma (India) Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Unimarck Pharma (India) Limited, buy the company report.
Charges & borrowings
Open charges
₹21.65 Cr
Satisfied charges
₹37 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 01 Jul 2023 | 100741152 | Others | ₹15.9 Lakh | Open | |
| 10 May 2017 | 100099413 | Others | ₹13.26 Cr | Open | |
| 17 Jul 1993 | 90181839 | Others | ₹8.24 Cr | Open | |
| 10 Sep 2021 | 100485631 | Hdfc Bank Limited | ₹85 Lakh | Satisfied | |
| 17 Apr 2015 | 10573176 | Punjab National Bank | ₹20 Lakh | Satisfied |
To see the full charge records of Unimarck Pharma (India) Limited, buy the company report.
Total charge records: 19 View all charges
Deals & funding
Unimarck Pharma (India) Limited has 5 deals on record (3 secondary share transfers, 2 funding rounds), with disclosed funding of ₹99.4 Lakh; the latest was in March 2022.
Total deals
5
Secondary share transfers
3
Funding rounds
2
Disclosed funding
₹99.4 Lakh
Deals on record (5 of 5)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2022 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: an individual |
| Mar 2012 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Mar 2012 | Funding round | ₹9.2 Lakh | Investors: 3 individuals |
| Mar 2009 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Oct 2008 | Funding round | ₹90.2 Lakh | Investors: 4 individuals |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Unimarck Pharma (India) Limited has 17 court cases on record: 13 filed by Unimarck Pharma (India), 4 filed against it. 7 cases are pending and 10 are disposed.
Total cases
17
Filed by the company
13
Filed against the company
4
Pending
7
Disposed
10
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 12 | 3 | 4 |
| District courts | 3 | 0 | 3 |
| Supreme Court | 2 | 1 | 0 |
Cases on record (5 of 17)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Delhi | Court case (C.O. (COMM.IPD-TM)) | Filed against the company by Manash Lifestyle Private Limited | Pending |
| District court, Chandigarh | Cheque dishonour complaint | Filed by the company against Honesty Labs P Ltd and 2 others | Pending |
| High Court of Delhi | Writ petition | Filed by the company against Union of India & Ors. | Pending |
| District court, Chandigarh | Cheque dishonour complaint | Filed by the company against individuals | Pending |
| District court, Chandigarh | Cheque dishonour complaint | Filed by the company against M/S Saraswati Surgical and 1 other | Pending |
To see the full case history of Unimarck Pharma (India) Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Unimarck Pharma (India) Limited was last rated by Crisil on 21 Apr 2021.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 21 Apr 2021 |
To see the full credit ratings and regulatory alerts of Unimarck Pharma (India) Limited, buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Unimarck Pharma (India) Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Unimarck Pharma (India) Limited has a workforce of 409 employees on its EPFO records as of Mar 28, 2024, across 2 active EPFO establishments.
Employee count
409
Active EPFO establishments
2
Employee growth
-9.71%
GST
Unimarck Pharma (India) has 10 GST registrations: 9 active and 1 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
10
Active
9
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 04AAACU2585M1Z3 | Chandigarh | Active | 01 Jul 2017 |
| 02AAACU2585M1Z7 | Himachal Pradesh | Active | 01 Jul 2017 |
| 03AAACU2585M1Z5 | Punjab | Active | 01 Jul 2017 |
| 08AAACU2585M1ZV | Rajasthan | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Unimarck Pharma (India) Limited, buy the company report.
Recent activity
Unimarck Pharma (India) Limited has 12 board changes on record since 1984: 4 appointments and 8 cessations. The latest: Harleen Kaur Bhatia ceased to be Additional Director on 29 Sep 2023.
AGM
Unimarck Pharma (India) Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Unimarck Pharma (India) Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Chandigarh.
Charges
A charge registered on 10 Sep 2021 via Charge ID 100485631 with Hdfc Bank Limited was fully satisfied on 08 Dec 2024.
Ceased
Harleen Kaur Bhatia ceased to be Additional Director.
Charges
A charge with Others amounted to Rs. 0.16 Cr with Charge ID 100741152 was registered on 01 Jul 2023.
Appointed
Harleen Kaur Bhatia was appointed as Director.
Charges
A charge with Others of Rs. 13.26 Cr registered on 10 May 2017 with Charge ID 100099413 was modified on 19 May 2022.
Ceased
Harsh Bhatia ceased to be Whole-Time Director.
Ceased
Bhupinderpal Singh Bhatia ceased to be Managing Director.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.85 Cr with Charge ID 100485631 was registered on 10 Sep 2021.
Charges
A charge with Others of Rs. 8.24 Cr registered on 17 Jul 1993 with Charge ID 90181839 was modified on 08 Jul 2020.
Charges
A charge registered on 14 Jan 2007 via Charge ID 10039339 with Hdfc Bank Limited was fully satisfied on 09 Jan 2020.
49 earlier events are in the company report.
Frequently asked questions
Unimarck Pharma (India) is an active public limited company based in Chandigarh, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 12 March 1984 (42+ years old) and is registered under CIN U24232CH1984PLC005768.
Unimarck Pharma (India) has 4 current directors:
- Mandeep Singh - Managing Director
- Gagandeep Bhatia - Whole-Time Director
- Harsh Bhatia - Whole-Time Director
- Harleen Kaur Bhatia - Director
The latest financial statements of Unimarck Pharma (India) on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Unimarck Pharma (India) is 04AAACU2585M1Z3, registered in Chandigarh. The company has 10 GST registrations in all, of which 9 are active and 1 is cancelled or inactive. Other active GSTINs include 02AAACU2585M1Z7 (Himachal Pradesh), 03AAACU2585M1Z5 (Punjab), 08AAACU2585M1ZV (Rajasthan).
The CIN (Corporate Identification Number) of Unimarck Pharma (India) is U24232CH1984PLC005768. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Unimarck Pharma (India) has 17 court cases on record: 13 filed by the company and 4 filed against it. 7 are pending. Most are in the high courts.
Unimarck Pharma (India) was incorporated on 12 March 1984, making it 42+ years old. It is registered with the Registrar of Companies, Chandigarh.
Unimarck Pharma (India) has 5 deals on record (3 secondary share transfers, 2 funding rounds), with disclosed funding of ₹99.4 Lakh; the latest was in March 2022.
The peers of Unimarck Pharma (India) by revenue are Ocean Healthcare Private Limited, Livealth Biopharma Private Limited, Uma Ayurvedics Private Limited, Stedman Pharmaceuticals Private Limited, And Healthcare Limited, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Harleen Kaur Bhatia ceased to be Additional Director on 29 Sep 2023. Harleen Kaur Bhatia was appointed as Director on 01 Apr 2023. Harsh Bhatia ceased to be Whole-Time Director on 15 Feb 2022. Unimarck Pharma (India) has 12 board changes on record in total.
Yes, Unimarck Pharma (India) is registered as a medium enterprise under Udyam registration (number: UDYAM-PB-20-0005338).